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Background. Interleukin-7 (IL-7) is a potent regulator of lymphocyte development, which has also significant effects on bone;
in fact it is a potent osteoclastogenic factor. Some human solid tumors produce high IL-7 levels, suggesting a potential IL-7 role
on tumor development and progression. Methodology. We studied 50 male patients affected by solid tumors, and their blood
samples were collected at tumor diagnosis. PBMCs were isolated and cultured with/without IL-7 to study its influence on
osteoclastogenesis. Serum and cell culture supernatant IL-7 levels were measured by ELISA. The quantitative analysis of IL-7
expression on T and B cells was performed by Real-Time PCR. Principal Findings. Serum IL-7 levels were highest in osteolytic
cancer patients, followed by cancer patients without bone lesions, and then healthy controls. We showed the IL-7 production
in PBMC cultures and particularly in monocyte and B cell co-cultures. A quantitative analysis of IL-7 expression in T and B cells
confirmed that B cells had a high IL-7 expression. In all cell culture conditions, IL-7 significantly increased osteoclastogenesis
and an anti-IL-7 antibody inhibited it. We demonstrated that IL-7 supports OC formation by inducing the TNF-a production and
low RANKL levels, which synergize in promoting osteoclastogenesis. Conclusions. We demonstrated the presence of high
serum IL-7 levels in patients with bone metastasis, suggesting the use of serum IL-7 level as a clinical marker of disease
progression and of bone involvement. Moreover, we showed the capability of IL-7 to stimulate spontaneous osteoclastogen-
esis of bone metastatic patients and to induce osteoclastogenesis in cancer patients without bone involvement. These findings
add further details to the disclosure of the mechanisms controlling bone metastasis in solid tumors.
Citation: Roato I, Brunetti G, Gorassini E, Grano M, Colucci S, et al (2006) IL-7 Up-Regulates TNF-a-Dependent Osteoclastogenesis in Patients Affected
by Solid Tumor. PLoS ONE 1(1): e124. doi:10.1371/journal.pone.0000124
INTRODUCTION
Interleukin-7 (IL-7) is a pleiotropic immune regulatory protein
predominantly produced by stromal cells and by cells at the
inflammatory sites [1]. IL-7 is fundamental for the early
development of lymphocytes and is a regulator of peripheral T
cell homeostasis by modulating the expansion of peripheral T-cell
populations in states of T cell depletion [2]. The production of IL-
7 by some human solid tumors suggests its potential impact on the
process of tumorigenesis [3,4], but it is unclear how IL-7 is
involved in solid tumor development and progression. IL-7
stimulates the progression of some types of lymphomas and
leukaemias [5,6] and in non-small cell lung cancer, it was reported
that IL-7 targeted gene therapy may be effective in modifying host
anti-tumor responses [7]. Recent studies on breast cancer describe
a quantitative association between the IL-7 signalling complex and
some clinico-pathological parameters: there is a trend towards
a higher expression of IL-7 and molecules of its signalling pathway
in breast cancer patients with poor prognosis [4]. Moreover, IL-7/
IL-7R mRNA was detected in different tumors, such as colorectal
[8], renal [9], lung and central nervous system cancers [10].
IL-7 is involved in the control of osteoclastogenesis, however
depending on the model considered, it displays either an inhibitory
or an activator effect on OCs [11], [12]. The OCs derive from
cells of the monocytic-macrophagic lineage, which fuse to form
bone-resorbing cells in the presence of Macrophage Colony
Stimulating Factor (M-CSF) and Receptor Activator of Nuclear
factor kB Ligand (RANKL) [13] or Tumor Necrosis Factor-
a (TNF-a) [14,15]. Weitzmann et al. demonstrated that systemic
administration of IL-7 stimulates osteoclastogenesis through T
cells by RANKL and TNF-a [16]. In addition, they showed
that TNF-a produced by T cells synergises with RANKL
increasing bone destruction in murine models of estrogen
deficiency [17,18].
The addition of exogenous cytokines is necessary to stimulate
osteoclastogenesis in patients without osteolysis and in healthy
controls. Previously, we demonstrated that peripheral blood
mononuclear cells (PBMCs) from cancer patients with osteolysis
differentiate spontaneously into OCs. In addition, we showed that
in patients with osteolysis the activation of osteoclastic precursors
depends on circulating tumor cells or on factors released from the
tumor site, such as TNF-a [15].
To better identify the factors involved in the spontaneous
osteoclastogenesis, present in bone metastatic patients, we focused
our studies on IL-7, since it have been associated with haemato-
logical malignancies and inflammatory diseases characterized by
a local and/or systemic bone loss [19–21].
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PLoS ONE | www.plosone.org 1 December 2006 | Issue 1 | e124IL-7 involvement in the bone metastasis formation and in the
spontaneous osteoclastogenesis of cancer patients adds a further
detail to the mechanisms of bone resorption and might be useful to
design novel therapeutic approaches for treatment and prevention
of bone metastasis.
RESULTS
IL-7 levels dosed in supernatants and sera are
higher in cancer patients than in healthy controls
We measured the IL-7 levels in 25 patient and healthy control
PBMC supernatants, collected at days 5 and 10 of culture. We
observed that IL-7 levels were significantly higher in patients than
in healthy controls at day 5, p,0,0006 (Fig. 1A). At day 10, the IL-
7 concentration was comparable to the one at day 5, both in
patients and in healthy controls (data not shown). To identify the
IL-7 source we performed co-colture experiments of monocytes
plus B or T cells and we measured its levels in supernatants at day
5 and 10. We showed that IL-7 levels were significantly higher in
cancer patients’ co-coltures of both monocytes plus T or B cells
than in healthy controls (p,0,0006) and remained nearly steady
between day 5 and 10. In our model, the purified B cell population
is responsible for IL-7 production: co-coltures of monocytes and B
cells showed the highest IL-7 levels. Both in PBMC cultures and in
monocytes plus T and B cells derived from patients without bone
lesions we measured low levels of IL-7, comparable to healthy
controls.
Besides, we tested serum levels of IL-7 in 50 patients affected by
solid tumors with or without metastasis at the time of diagnosis.
Fig. 1B showed that IL-7 serum levels were significantly higher in
patients with bone metastasis compared to patients without bone
lesions and healthy controls, p,0,0001. The mean IL-7 value was
17,6861,24 pg/ml for osteolytic patients, 10,7360,10 pg/ml for
patients without bone lesion and 5,5660,30 pg/ml for healthy
controls. We examined the potential differences in serum IL-7
levels according to the various types of tumor and specifically we
considered prostate cancer, NSCLC and SCLC. We identified
significant differences in the mean value of IL-7 (p#0,02), which
were 19.8966.30 pg/ml for prostate cancer, 14.665.95 pg/ml for
NSCLC and 7.5664.09 pg/ml for SCLC.
Evaluation of IL-7 expression in T and B cells with
(RQ-PCR)
We analysed the expression of IL-7 on freshly purified T and B
cells by RQ-PCR. The analyzed transcripts exhibited high
linearity amplification plots (r.0.99) and the efficiencies of both
PCR reactions were quite similar. As shown in Fig. 2, we did not
measure significant differences in the expression of IL-7 in both
patients and healthy controls’ T cells, while in healthy controls’ B
cells the IL-7 expression was five-fold lower than in patients. The
relative expression of IL-7 was seven-fold higher in B cells than in
T cells in cancer patients. We did not appreciate any significant
differences in IL-7 expression in cancer patients with or without
bone metastasis (Fig. 2).
Effects of IL-7 on osteoclastogenesis
The OC differentiation was verified by the presence of multi-
nucleated/TRAP positive cells from cancer patient and healthy
control PBMCs (Fig. 3A–B lines, respectively). PBMCs were
cultured at different doses of IL-7, that resulted in significantly
increased osteoclastogenesis with 2,5 and 10 ng/ml of IL-7 in
osteolytic patients and in osteoclastogenesis stimulation for patients
Figure 1. IL-7 levels in cell culture medium and serum. IL-7 levels in
cancer patients with/without bone metastases and in healthy controls
were analysed by ELISA. At day 5, supernatants of patients’ PBMC
cultures and monocyte plus T and B cell co-colture had IL-7 levels
higher than healthy controls (A). Bone metastatic patients had
significantly higher serum levels of IL-7 compared to patients without
bone metastasis and healthy controls (B). Samples were assayed in
duplicate and data were expressed as mean values.
doi:10.1371/journal.pone.0000124.g001
Figure 2. Quantitative analysis of IL-7 expression in T and B cells. IL-7
expression was evaluated by RQ-PCR using 2
2DDCt method. B cells
derived from cancer patients expressed significantly higher levels of IL-7
compared to T cells. Both T and B cells from healthy controls expressed
less IL-7 than patients. The control bar represents the negative control:
IL-7 expression in H522 cell line. Data are means6SE of nine
independent experiments.
doi:10.1371/journal.pone.0000124.g002
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ml, IL-7 had not a stimulatory effect on osteoclastogenesis
(Fig. 3C). By adding a neutralizing anti-IL-7 antibody on osteolytic
patients’ PBMC, we observed a dose-dependent inhibition of
spontaneous osteoclastogenesis, p,0,01 (Fig. 3D). We character-
ized OCs also for the expression of aVb3, a typical OC marker.
Both OCs derived from culture with and without IL-7 expressed
aVb3, as shown in Fig. 3E.
The ability of IL-7 to induce OC formation was tested in
cultures of purified monocytes alone and in co-cultures with
purified T or B cells treated or untreated with IL-7 at 2,5 and
15 ng/ml. Our results showed that monocytes alone were not able
to support significant OC formation in either the presence or
absence of IL-7, in both cancer patients and healthy controls (data
not shown). Moreover, we demonstrated that co-cultures of
monocytes and T cells both from bone metastatic patients and
healthy controls resulted in a significant induction of OC formation
by adding 2,5 ng/ml compared to basal condition, p , 0,001,
while the dose of 15 ng/ml did not elicit a significant stimulatory
effect on osteoclastogenesis (Fig. 4A). Co-cultures of monocytes and
B cells in presence of IL-7 showed an increase in OC number, but it
was not statistically significant (Fig. 4B). In all culture conditions,
we observed a comparable osteoclastogenesis in patients without
bone metastases and in healthy controls (data not shown).
Since we showed that spontaneous osteoclastogenesis depends
on contact between monocytes and lymphocytes [15], we
investigated whether T and B cells were necessary for IL-7-
dependent OC differentiation. We cultured purified monocytes
with IL-7-treated conditioned medium from T and B cells and we
did not observe OC differentiation (data not shown). Thus, cell-to-
cell interaction between lymphocytes and monocytes are required
for solid tumor dependent osteoclastogenesis.
Figure 3. Effect of IL-7 on osteoclastogenesis in vitro. TRAP
+ multinucleated cells were identified as OCs at the end of culture in both bone
metastatic patients (line A) and healthy controls (line B). PBMC cultures were plated and stimulated with IL-7 (0,5–1–2,5–10–15 ng/ml). The
osteoclastogenesis significantly increased at 2,5 ng/ml of IL-7 compared to the unstimulated condition (C). The anti-IL-7 antibody added in cell
culture determined a dose-dependent inhibition of spontaneous osteoclastogenesis in bone metastatic patients (D). Multinucleated/TRAP positive
cells, derived both from culture with and without IL-7, expressed also aVb3 (E).
doi:10.1371/journal.pone.0000124.g003
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PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e124Figure 4. IL-7 stimulates osteoclastogenesis in co-coltures of monocytes and T or B cells. The different subpopulations were isolated from PBMCs
and co-coltures of monocytes and T or B cells (M+T; M+B) were made. By adding 2,5 ng/ml of IL-7 in co-coltures we observed an increase in
osteoclastogenesis, which was statistically significant for T cells (A) and not for B cells (B). At 15 ng/ml of IL-7, there were not significant effects in
both the co-coltures.
doi:10.1371/journal.pone.0000124.g004
Figure 5. IL-7 increases OC bone resorbing activity. PBMC resorption activity with/without IL-7 were showed for bone metastatic patients (line A)
and healthy controls (line B). The basal resorbing activity of OCs derived from patients was significantly higher compared to healthy controls,
#p#0,0001 (C). The percentage of resorption area was significantly increased with 2,5 ng/ml of IL-7, both in patients and in healthy controls,
*p#0,002 (C). At 15 ng/ml IL-7 did not elicit a significant variation of resorption area. The data represent the means6SE from ten independent
experiments.
doi:10.1371/journal.pone.0000124.g005
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Since we showed that IL-7 had effects in stimulating osteoclasto-
genesis, we verified whether there was a similar stimulatory action
on bone resorbing activity. By analysing the resorption area on
biocoated slices, we demonstrated that in presence of IL-7 at
2,5 ng/ml the OCs increased the bone resorbing activity of
osteolytic patients and stimulated the healthy controls’ resorption
(Fig. 5A–B lines, respectively). The basal resorption activity of
OCs derived from patients was significantly higher compared to
healthy controls,
#p#0,0001 (Fig. 5C). After stimulation with IL-7
at 2,5 ng/ml, the bone resorbing activity of OCs was significantly
augmented both in patients and in healthy controls, *p#0,002
(Fig. 5C). At 15 ng/ml of IL-7, we did not observe any statistically
significant variation on bone resorbing areas.
IL-7 affects TNF-a and RANKL release in culture
We assessed the IL-7 ability to induce TNF-a and RANKL
secretion in PBMC cultures and monocyte plus T or B cell co-
coltures at day 5 and 10. The basal levels of TNF-a were similar in
PBMC media at day 5 and 10 and they significantly increased by
adding 2,5 ng/ml of IL-7, p,0,002 (Fig. 6A). Co-cultures of
monocytes and T or B cells showed basal TNF-a levels higher at
day 10 than at day 5. Monocytes plus T cells displayed an IL-7
dose-dependent increase of TNF-a level both on days 5 and 10,
p,0,01 (Fig. 6B). At 15 ng/ml of IL-7, TNF-a values reached
a plateau level both in PBMC cultures and in monoytes plus T cell
co-coltures (Fig. 6A–B). At day 5, co-coltures of monocytes and B
cells showed a significant enhancement of TNF-a amount at
15 ng/ml, whereas at day 10 we measured a significant increase in
TNF-a levels at 2.5 ng/ml, that was unchanged at 15 ng/ml of IL-
7, p#0,01 (Fig. 6C).
We found low RANKL levels in culture media collected from
PBMC and monocyte plus T or B co-coltures. In particular, in the
IL-7 treated cells there were not significant differences compared
to unstimulated controls (Table 1). To further study the
involvement of TNF-a and RANKL we cultured cancer patients’
PBMC in presence of IL-7 and a neutralizing anti-TNF-a antibody
or osteoprotegerin (OPG) in different concentrations. Both the
inhibitors determined a dose-dependent inhibition of bone resorb-
ing activity (data not shown) and of osteoclastogenesis, that was
stronger in cultures treated with anti-TNF-a (Fig. 7A) than with
OPG (Fig. 7B). Thus, our data demonstrated that IL-7 supports
osteoclastogenesis by inducing mainly the TNF-a production and
low levels of RANKL.
DISCUSSION
Over the last years, many studies investigated the cross-talk
between immune system and bone, and IL-7 appeared as an
important factor in these interactions [12,22,23]. IL-7 is known to
be a powerful inducer of T and B lymphopoiesis, moreover many
studies link IL-7 to inflammatory diseases [21,24,25] and bone loss
in estrogen deficiency conditions [22,26]. Our study focused on
IL-7 involvement in the spontaneous osteoclastogenesis occurring
in cancer patients with osteolytic metastasis. We showed
significantly higher IL-7 levels in supernatants derived from
PBMC cultures and co-coltures of monocytes and T or B cells of
cancer patients compared to healthy controls. Our data describe
for the first time the presence of elevated IL-7 levels in sera of male
patients affected by solid tumors, in fact the only data available in
literature, concerning IL-7 serum levels in patients affected by
solid tumors are related to gynecologic cancers [27–29], while
elevated serum IL-7 levels were previously detected in other
pathologies with bony involvement, such as multiple myeloma
Figure 6. IL-7 up-regulates TNF-a production in cell culture media.
PBMC and monocytes plus T or B cells were cultured in absence or
presence of IL-7. Supernatants were collected at days 5 and 10 to dose
TNF-a. PBMCs showed the same TNF-a basal level, which increased at
2,5 ng/ml of IL-7 and reached the maximum value at 15 ng/ml, (A).
Monocytes plus T cells (M+T) (B) and monocytes plus B cells (M+B) (C)
had a TNF-a basal level higher at day 10 than at day 5, but both
supernatants showed the peak value at 2,5 ng/ml of IL-7, and remained
roughly costant at 15 ng/ml. The data were means6SE of 25
supernatants collected at day 5 and 10 for both patients and healthy
controls.
doi:10.1371/journal.pone.0000124.g006
Table 1. RANKL levels in cell culture media.
......................................................................
RANKL pg/ml
Day 5 Day 10
PBMC 0 ng/ml IL-7 1.91(61.00) 6.34 (62.85)
2.5 ng/ml IL-7 0.1(60.1) 2.28(62.28)
15 ng/ml IL-7 2.6(61.31) 3.94(63.94)
M+T 0 ng/ml IL-7 0.84(60.84) 5.86(63.26)
2.5 ng/ml IL-7 2.14(62.14) 6.21(60.23)
15 ng/ml IL-7 2.32(62.32) 9.53(66.45)
M+B 0 ng/ml IL-7 0.40(60.40) 0.83(60.53)
2.5 ng/ml IL-7 0.62(60.23) 1.53(61.53)
15 ng/ml IL-7 0.84(60.14) 1.19(60.65)
doi:10.1371/journal.pone.0000124.t001
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PLoS ONE | www.plosone.org 5 December 2006 | Issue 1 | e124[19], rheumatoid arthritis [30] and systemic juvenile rheumatoid
arthritis [31]. It is interesting to note that patients affected by bone
metastatic cancer had an IL-7 value higher than non-bone
metastatic ones, and these latter showed an intermediate IL-7
serum value between bone metastatic patients and healthy
controls. The high IL-7 serum levels might be interpreted as
a signal of disease progression towards the metastatic phenotype in
some non-bone metastatic tumor patients. The analysis of the
available data showed that NSCLC and prostate cancer had
a statistically significant higher IL-7 serum levels compared to
SCLC cases. However, in all the specific cancer groups (NSCLC,
prostate cancer and SCLC) we found that patients with bone
metastasis had higher IL-7 levels than patients without osteolysis.
These findings might infer that in different tumor types the
increase of IL-7 serum levels might be useful for early diagnosis of
metastatic bone lesions. Literature data support the IL-7 pro-
duction by different tumor types [4,8,10] apart from stromal cells
in bone microenvironment. Previously reported data showing the
role of B cells in IL-7 production [6,19,23,32], were confirmed by
our finding that B cells produced IL-7 and this production was
higher than T cell one.
In this study we demonstrated that IL-7 at 2,5 ng/ml increased
osteoclastogenesis in patients’ cultures of PBMCs and co-coltures
of monocytes plus T or B cells, while at the dose of 15 ng/ml, IL-7
did not affect osteoclastogenesis. To explain this result we
hypotesize that, at high doses, IL-7 stimulates a differentiation
switch from OCs towards dendritic cells since in cultures with
15 ng/ml of IL-7 we observed only few OCs and mainly
undifferentiated macrophages or cells with dendritic cells mor-
phology. This hypothesis is supported by some studies showing
that IL-7 regulates dendritic cells differentiation from PBMC
cultures [33,34]. Since literature data link IL-7 to TNF-a and
RANKL-dependent osteoclastogenesis [16,19,35], we measured
their levels in culture media. In detail, we showed that IL-7
enhances in a dose-dependent manner TNF-a levels in PBMC
culture media and in co-coltures of monocytes and T or B cells.
We hypothesize that TNF-a levels reached maximal values in the
PBMC cultures probably due to a cooperative release of TNF-a by
monocytes [21], T and B cells stimulated by IL-7. We observed
a little and not statistically significant dose-dependent increase of
RANKL release from day 5 to day 10 of culture compared to
unstimulated condition. According to literature data [36,37] we
think that these low levels of RANKL are synergistic with TNF-a in
promoting osteoclastogenesis. In fact we observed that both anti-
TNF-a antibody and OPG caused a dose-dependent inhibition
of IL-7-induced osteoclastogenesis. The anti-TNF-a antibody
reached an OC inhibition plateau at 90% while OPG treatment
of cell cultures reached a plateau of OC differentiation inhibition
at 50%. Further increase in OPG concentrations, in an attempt
to reach an higher level of inhibition, was found to be toxic for
the cultured cells. This observation suggests that in our model
TNF-a might have a stronger role in OC formation than RANKL;
it is conceivable that both factors may synergize in OC
differentiation.
These last results demonstrate that TNF-a plays a fundamental
role in IL-7-induced osteoclastogenesis in patients affected by solid
tumor. Moreover, the pivotal role exerted by TNF-a in our
systems was also supported by the fact that in freshly isolated T
and B cells from patients we did not find RANKL expression,
while TNF-a was strongly present. TNF-a enhancement by IL-7 is
also present in other pathological conditions, characterized by
a local and/or systemic bone loss, such as rheumatoid arthritis
[30] or postmenopausal osteoporosis [38].
In conclusion, we propose a new physiopathologic mechanism
with a key role of IL-7 in the formation of solid tumor bone
metastasis. We demonstrated that IL-7, produced mainly by B
cells in cell culture, directly sensitizes T cells to produce pro-
osteoclastogenic factors, such as TNF-a and RANKL, and
enhances spontaneous osteoclastogenesis. It could be useful to
analyse a large number of patients for each different tumor type, in
order to set an IL-7 cut off value, representative of a warning
threshold for clinicians. This could allow to follow the bone
metastatic disease both at diagnosis and during treatments.
MATERIAL AND METHODS
Patients
Samples from peripheral blood (PB) were obtained from 50 male
patients affected by solid tumors and 50 healthy controls, matched
for age and sex. The main clinical characteristics of patients, aged
from 50 to 84 years (median 65611,01 SD), are listed in Table 2.
The patients’ samples were collected at diagnosis to exclude biases,
including recent chemo/hormono-therapy and pre-existing or
non-related bone pathologies. We decided not to include breast
Figure 7. Effect of anti-TNF-a and OPG on IL-7-induced osteoclastogenesis. The addition of both OPG and anti-TNF-a caused a dose-dependent
inhibition of IL-7-induced osteoclastogenesis. The anti-TNF-a antibody caused a strong osteoclastogenesis inhibition, about 90% (A) while OPG
caused a 50% inhibition (B).
doi:10.1371/journal.pone.0000124.g007
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steroids or hormonal therapies.
Healthy controls showed a normal bone metabolism (evaluated
by bone densitometry) and were not under medications, such as
steroids that could increase osteoclastogenesis. Informed consent
from patients and healthy controls was obtained to comply with
institutional policies.
Cell cultures
PBMCs, collected from cancer patients and healthy controls, were
isolated after centrifugation over a density gradient, Lymphoprep
(Nycomed Pharma, Norway) and cultured in a-MEM, supple-
mented with 10% FBS, penicillin 100 U/ml and streptomycin
100 mg/m (Cambrex, Walkersville MD). To obtain fully differen-
tiated human OCs, PBMCs were cultured with/without rhIL-7 at
different doses (0,5–1–2,5–10 and 15 ng/ml), R&D Systems
(Abingdon, UK). Culture supernatants were collected on days 5
and 10, when medium was either refreshed and supplemented or
not with IL-7. For some experiments, patient PBMCs were
cultured with different doses of anti-IL7 (50–100–300 ng/ml),
R&D Systems (Abingdon, UK). Cultures were stopped after
15 days, mature OCs were identified as multinucleated cells
containing three or more nuclei and positive for the expression of
TRAP (Tartrate-resistant acid phosphatase, Sigma Aldrich, St.
Louis MO) and aVb3 (vitronectin receptor) kindly provided by
Prof. G. Tarone. To evaluate bone resorbing activity, for 21 days
PBMCs were cultured on Biocoat Osteologic bone cell culture
system (BD Biosciences Bedford, MA) with/without IL-7, then
cells were removed and resorption lacunae were identified by light
microscopy.
For some experiments PBMCs were cultured in presence of
increasing concentration of a neutralizing anti-TNFa (4–5 mg/ml)
antibody and osteoprotegerin (OPG 10–20 ng/ml), PeproTech
(London, UK).
Isolation of monocytes, T and B cells
Monocytes, T and B cells were isolated from PBMCs by an
immunomagnetic selection using MACs microbeads (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany), according to the
manufacturer’s instructions. The purity of monocytes, T and B
cells, obtained after separation, was 95–98%, as assessed by flow
cytometry. Isolated cells were plated according to the human
physiological concentrations: 10% monocytes and 30% lympho-
cytes (70% for T and 30% for B) with/without IL-7.
ELISA (Enzyme-Linked Immunosorbent Assay)
The amount of IL-7 in cell culture supernatant and serum was
determined by ELISA kit (sensitivity was 0,156 to 20 pmol/L and
0 to 16 pmol/L, respectively. R&D Systems, Abingdon UK).
TNF-a (Biosource, Nivelles Belgium) and RANKL (Biomedica
Gruppe, Wien Austria) ELISA kit were performed on culture
supernatants, the sensitivity range was 0 to 1500 pmol/L and 0 to
8 pmol/L, respectively.
Quantitative analysis of IL-7 gene expression
Total RNA was extracted from T and B cells and the first-strand
cDNA synthesis was performed as previously described [15].
Quantitative analysis of IL-7 was performed with Real-Time
Quantitative PCR (RQ-PCR) using b-actin as housekeeping
control. RT-PCR was carried out using the iCycler iQ
TM system
(Bio Rad, CA, USA). PCR primers and TaqMan probes were
designed using Primer Express v1.0 software and synthesized by
Applied Biosystems (Warrington, UK). TaqMan probe specific for
Table 2. Patient characteristics.
......................................................................
Patient Cancer Metastasis site Age TNM
1 Stage
2
1 SCLC none 56 Extended disease
3 –
2 SCLC liver 79 Extended disease
3 –
3 SCLC adrenal gland 52 Extended disease
3 –
4 SCLC bone 64 Extended disease
3 –
5 NSCLC none 84 T1N0M0 I
6 NSCLC none 69 pT1N0M0 I
7 NSCLC none 78 pT1N0M0 I
8 NSCLC bone 52 T1N0M1 IV
9 NSCLC none 74 pT2N0M0 I
10 NSCLC none 50 T2N0M0 I
11 NSCLC none 76 T2N0M0 I
12 NSCLC none 56 pT2N0M0 I
13 NSCLC none 66 pT2N1M0 II
14 NSCLC none 62 T2N2M0 IIIA
15 NSCLC none 72 T2N2M0 IIIA
16 NSCLC none 58 T2N3M0 IIIB
17 NSCLC adrenal gland 63 T2N0M1 IV
18 NSCLC bone 70 T2N0M1 IV
19 NSCLC bone 57 T2N2M1 IV
20 NSCLC adrenal gland, bone 50 T2N2M1 IV
21 NSCLC bone 61 T2N2M1 IV
22 NSCLC bone, liver 50 T2N3M1 IV
23 NSCLC adrenal gland 71 T2N3M1 IV
24 NSCLC bone 57 T2N3M1 IV
25 NSCLC none 53 T3NXM0 IIIA-B
26 NSCLC none 56 T3N2M0 IIIA
27 NSCLC none 81 pT3N2M0 IIIA
28 NSCLC lung 76 T3N2M1 IV
29 NSCLC bone 71 T3N2M1 IV
30 NSCLC bone 66 T3N3M1 IV
31 NSCLC adrenal gland, brain 54 T3N3M1 IV
32 NSCLC none 75 T4N0M0 IIIB
33 NSCLC brain, bone 59 T4N3M1 IV
34 NSCLC surrenal 45 T4N3M1 IV
35 NSCLC bone 77 T4N3M1 IV
36 NSCLC liver 77 T4N3M1 IV
37 NSCLC brain 63 T4N3M1 IV
38 prostate bone 62 T3N0M1 IV
39 prostate bone 84 pT3bN1M1 IV
40 prostate bladder 71 T3N2M1 IV
41 prostate bone 64 T3N2M1 IV
42 prostate none 68 T4N0M0 IIIB
43 prostate bone 66 T4N0M1 IV
44 prostate bone 64 T4N0M1 IV
45 colon bone 59 pT3N1M1 IV
46 colon bone 66 pT4N0M1 IV
47 bladder bone 86 pT3NXM1 IV
48 bladder bone 75 pT3bN2M1 IV
49 pancreas multiple 36 T4N2M1 IV
50 kidney bone 74 pT1aN0M1 IV
1TNM interantional classification: T(primary tumor), N(primary regional
lymphonodes), M (metastasis), p (post-surgery)
2tumor hystologic grading
3Veterans Administration Lung Cancer Study Group (VALCSG)
doi:10.1371/journal.pone.0000124.t002
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PLoS ONE | www.plosone.org 7 December 2006 | Issue 1 | e124IL-7 (59-TGAGAGTGTTCTAATGGTCAGCATCGATCAAT-
39) and for b-actin (59- CGTCACCAACTGGGACGACATGG-
39) were both labelled at the 59 end with 6-carboxy fluorescein
(FAM) and the 39 end with 6-carboxy-tetrametil rhodamine
(TAMRA). The IL-7 primer sequences were: sense 59-TGAAGG-
TAAAGATGGCAAACAA-39; antisense 59-CAATTTCTTTCA-
TGCTGTCCAA-39. The b-actin primer sequences were: sense
59-CCCTGAAGTACCCCATCGA-39; antisense 59- AAGGTG-
TGGTGCCAGATTTTC-39. Reactions for IL-7 and b-actin
quantification were performed in a 25 ml final volume with 2 mlo f
sample cDNA, 1X iQ Supermix (Bio Rad), 0,4 mM of each primer
and 0,4 mM of the IL-7 probe. The amplification conditions for
quantization were: 95uC for 15 minutes and 50 cycles of 95uC for
15 seconds and 58uC for 1 minute.
We tested a series of cell lines for the IL-7 expression and we
chose , as positive control, MG63, an osteosarcoma cell line that
expressed at high level IL-7. As negative control we used H522,
a non-small cell lung cancer cell line. Relative IL-7 quantization in
T and B lymphocytes, expressed as –fold variation over control
(H522), was calculated after determination of the difference
between CT (threshold cycle) of the given gene A (IL-7) and that of
the calibrator gene B (b-actin) using the 2
2DD
CT method [39]. CT
values are means of duplicate measurements. To validate the use
of the 2
2DDCT method, serial dilutions (ranging from 10
0 to 10
25)
of MG63 cDNA were used to obtained a standard curve.
Statistical analyses
Statistical analyses were performed with the Statistical Package for
the Social Sciences (spssx/pc) software (SPSS, Chicago, IL). We
compared the results by means of student’s paired t test. The
results were considered statistically significant for p,0,05.
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